Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial Not Allowed)

The National Institutes of Health (NIH), under the U.S. Department of Health and Human Services, has issued a funding opportunity titled Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial Not Allowed). This initiative is administered by the National Institute of Dental and Craniofacial Research on behalf of the NIH Common Fund, which supports cross-cutting biomedical research programs designed to accelerate discovery and translation into prevention strategies and treatments. The program is intended to expand the scientific value and usability of large-scale datasets generated through prior Common Fund initiatives. The primary purpose of this funding opportunity is to support small, focused research projects that enhance the utility and accessibility of selected Common Fund datasets. Applicants are expected to demonstrate how their work will generate new hypotheses, enable novel discoveries, or improve the integration and usability of these datasets. Projects must substantially leverage data from at least two eligible Common Fund programs or use Molecular Transducers of Physical Activity in Humans data. The initiative emphasizes innovation in data science, including artificial intelligence, machine learning, computational modeling, and advanced data integration techniques. Funding is provided through the R03 Small Grant Program, which supports discrete, well-defined projects that can be completed within a one-year period. Applicants may request up to 200,000 dollars in direct costs for the project duration. Funds are intended primarily for data analysis and tool development; experimental validation activities are allowed but limited to 20 percent of the total budget. Awardees are also expected to participate in meetings and share outputs such as tools, workflows, and annotated datasets through public repositories to enhance accessibility and reproducibility. Eligibility for this opportunity is broad and includes higher education institutions, nonprofits, for-profit organizations, and various government entities such as state, local, and tribal governments. However, foreign organizations are not eligible to apply, and foreign subawards are prohibited. Individual investigators must have the necessary expertise and institutional support to carry out the proposed research. Certain individuals affiliated with specific NIH data coordinating centers or related programs are excluded from eligibility. The application process requires submission through Grants.gov or NIH systems such as ASSIST or institutional system-to-system solutions. Applicants must comply with all NIH application instructions, including registration in systems such as SAM, eRA Commons, and Grants.gov. Required components include a detailed research plan, budget justification, and data management and sharing plan. Applications must demonstrate feasibility, scientific rigor, and alignment with program goals. Review criteria focus on significance and innovation, methodological rigor and feasibility, and investigator expertise and institutional environment. The timeline for this opportunity includes an opening date of May 23, 2026, and a submission deadline of June 23, 2026. Applications are reviewed in November 2026, followed by advisory council review in January 2027, with the earliest project start date anticipated in April 2027. This is a one-time funding opportunity with no explicit indication of recurrence. Applicants are encouraged to submit early to allow time for corrections before the deadline. Overall, this funding opportunity aims to maximize the impact of existing biomedical datasets by encouraging innovative reuse, integration, and analysis. By supporting pilot-scale projects, NIH seeks to broaden the scientific community’s engagement with Common Fund data resources and generate insights that can lead to larger-scale research efforts and future funding opportunities.

Emphasize integration of multiple datasets, demonstrate strong feasibility within one year, and clearly articulate innovation and impact on biomedical research community